FIELD: medicine.
SUBSTANCE: present invention relates to a method for personalized treatment of chronic renal disease in patients with diabetic nephropathy, according to which personalization of drug selection, mode and duration of monotherapy or preparations for combined therapy and adding epigallocatechin-3-gallate as an antioxidant depending on the detected urine proteomic profile, intermolecular interactions of the detected peptides and urine proteins.
EFFECT: higher clinical effectiveness in chronic renal disease accompanying diabetic nephropathy.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF ISOLATED SYSTOLIC ARTERIAL HYPERTENSION OF 1 DEGREE IN PATIENTS IN EARLY PERIOD OF OLD AND SENILE AGE | 2019 |
|
RU2726071C1 |
| METHOD FOR DIAGNOSTICS OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2017 |
|
RU2641964C1 |
| BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES-RELATED CONDITIONS | 2011 |
|
RU2596486C2 |
| METHOD FOR EARLY PREDICTION OF THE RISK OF DEVELOPMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2793531C1 |
| METHOD OF PREDICTING CHARACTER OF PROGRESSING COURSE OF CHRONIC KIDNEY DISEASE | 2010 |
|
RU2430364C1 |
| METHOD OF ASSESSING AGE-RELATED CHANGES OF HUMAN CARDIOVASCULAR SYSTEM | 2012 |
|
RU2485886C1 |
| METHOD FOR DIAGNOSING EARLY CHRONIC RENAL DISEASE IN CHILDREN | 2020 |
|
RU2753581C1 |
| METHOD FOR ASSESSING INTESTINAL EPITHELIAL BARRIER PERMEABILITY IN PATIENTS RECEIVING HEMODIALYSIS TREATMENT | 2023 |
|
RU2817667C1 |
| METHOD OF TREATMENT OF ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2021 |
|
RU2750523C1 |
| METHOD FOR DIAGNOSING PRECLINICAL SECONDARY NEPHROPATHIES IN CHILDREN | 2020 |
|
RU2753588C1 |
